Codone Biotechnology

Ownership

Private

Therapeutic Areas

Rare DiseasesNephrology

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Suppressor-tRNAs

Codone Biotechnology General Information

Codone Biotechnology is developing transformative medicines based on suppressor-tRNAs for diseases caused by premature termination codons. They have presented data on their lead tRNA candidates in disease models.

Contact Information

Website

http://www.codonebio.com/en

Primary Industry

Biotech

Corporate Office

Shanghai,
China

Drug Pipeline

No pipeline data available

For full access to Codone Biotechnology's pipeline data

Book a demo

Key Partnerships

University of Massachusetts

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Codone Biotechnology Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Codone Biotechnology's complete valuation and funding history, request access »